Tri­umvi­ra snags $55M Se­ries A to guide TAC tech­nol­o­gy to the clin­ic

Tri­umvi­ra Im­muno­log­ics wants to bring its T-cell anti­gen cou­pler (TAC) tech­nol­o­gy to the clin­ic ear­ly next year, and it plans on rid­ing a $55 mil­lion Se­ries A to get there.

Paul Lam­mers

The Austin, TX-based biotech an­nounced the com­ple­tion of its fi­nanc­ing round on Thurs­day. And now pres­i­dent and CEO Paul Lam­mers says it’s “all hands on deck” to sub­mit an IND for the com­pa­ny’s HER2-di­rect­ed TAC for sol­id tu­mor pa­tients. Lam­mers hopes the TAC will be ready for hu­man test­ing in late Q1 of 2021.

The fund­ing “will give us a nice run­way to do a lot of fun stuff,” he said. The CEO helmed Mir­na Ther­a­peu­tics un­til a re­verse merg­er with Syn­log­ic in 2017.

Leaps by Bay­er and North­pond Ven­tures led the Se­ries A, and Ocean­pine Cap­i­tal, Vi­va Biotech Hold­ings, Bloom Bur­ton, and the Cen­tre for Com­mer­cial­iza­tion of Can­cer Im­munother­a­py joined in.

The com­pa­ny’s TAC tech is de­signed to ac­ti­vate can­cer-fight­ing T cells “in a nat­ur­al fash­ion,” Lam­mers said. “We tru­ly think that a nat­ur­al ac­ti­va­tion of the T cell is a step for­ward in T-cell ther­a­py, and that’s re­al­ly what we’re try­ing to ac­com­plish with our TAC T cell.”

When not in con­tact with can­cer cells, TAC T cells are to­tal­ly in­ac­tive — as op­posed to CAR-T cells which may be­come ex­haust­ed, Lam­mers said. Plus, the CEO said the TAC tech­nol­o­gy could be safer than cur­rent treat­ments.

“Be­cause of the risk of tox­i­c­i­ties, in fact, it’s on­ly a lim­it­ed num­ber of pa­tients that are el­i­gi­ble to re­ceive these kinds of CAR-T ther­a­pies to be­gin with. If we can ex­pand that pop­u­la­tion with a safer en­gi­neered T cell, that would be fan­tas­tic,” he said.

It’ll all come down to the hu­man stud­ies, which will ini­tial­ly in­clude a va­ri­ety of par­tic­i­pants, in­clud­ing gas­tric, ovar­i­an and breast can­cer pa­tients.

Juer­gen Eck­hardt

Tri­umvi­ra will al­so use Se­ries A fund­ing to de­vel­op its al­lo­gene­ic TAC, for which it hopes to sub­mit an IND at the end of next year. In No­vem­ber, the com­pa­ny re­ceived fast-track des­ig­na­tion from the FDA for its TAC01-CD19 as a po­ten­tial third-line ther­a­py for pa­tients with re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL). The com­pa­ny was set to be­gin a Phase I/II study by the end of 2019, but then the Covid-19 pan­dem­ic struck.

For now, Tri­umvi­ra is putting its CD19 TAC on the back burn­er to fo­cus on its sol­id tu­mors TAC.

“Sol­id tu­mors is where we think our biggest val­ue propo­si­tion is for in­vestors and for the com­pa­ny, and that’s re­al­ly some­thing that we’d like to ex­pand in the com­ing years,” Lam­mers said.

Juer­gen Eck­hardt, head of Leaps by Bay­er, said Tri­umvi­ra’s pipeline brings forth a “unique op­por­tu­ni­ty in the de­vel­op­ment of next-gen­er­a­tion cell ther­a­pies that promise to ad­dress pre­vi­ous­ly in­cur­able can­cers.” He and VP of ven­ture in­vest­ments Jak Knowles will join the biotech’s board of di­rec­tors.

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA have vowed not to let politics get in the way of science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped health agencies under his purview — including the FDA — of their rulemaking ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

AstraZeneca has unveiled the final, mature overall survival data that cemented Lynparza’s first approval in prostate cancer approval — touting its lead against rivals with the only PARP inhibitor to have demonstrated such benefit.

But getting the Merck-partnered drug to the right patients remains a challenge, something the companies are hoping to change with the new data cut.

The OS numbers on the subgroup with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer are similar to the first look on offer when the FDA expanded the label in May: Lynparza reduced the risk of death by 31% versus Xtandi and Zytiga. Patients on Lynparza lived a median of 19.1 months, compared to 14.7 months for the anti-androgen therapies (p = 0.0175).

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Eli Lilly CSO Dan Skovronsky (file photo)

#ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mutant non-small cell lung cancer has turned up some promising — although decidedly early — results, fueling the idea that there’s yet room to one up on third-generation tyrosine kinase inhibitors.

Twenty out of 20 advanced NSCLC patients had a response after taking a combination of an in-house TKI dubbed lazertinib and amivantamab, a bispecific antibody targeting both EGFR and cMET engineered on partner Genmab’s platform, J&J reported at ESMO. All were treatment-naïve, and none has seen their cancer progress at a median follow-up of seven months.

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.

Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.

There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.

The deal, announced last weekend, will give California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.